Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can we safely skip a Pre-Transplant bile duct scan? a trial tests the limits of simpler donor checks

NCT ID NCT07715500

Knowledge-focused Sponsor: Institute of Liver and Biliary Sciences, India Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This trial studies whether omitting a routine magnetic resonance cholangiopancreatography (MRCP) scan in healthy living liver donors affects the rate of bile duct complications in transplant recipients. About 100 donors aged 18–55 will be randomly assigned to receive or skip the MRCP before surgery. The goal is to see if the scan is truly necessary for safe surgical planning or if intraoperative assessment alone is sufficient.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Magnetic Resonance Cholangiopancreatography (MRCP) scan
What this could lead to
If skipping routine MRCP before liver donation proves safe, it could simplify donor evaluation and reduce healthcare costs without harming transplant outcomes.
What could go wrong
This is a single-center trial with 100 participants, so results may not apply broadly. The study is designed to test non-inferiority, not superiority, and missing a subtle bile duct variation could still increase recipient complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

Aug 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 55 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * All prospective voluntary healthy liver donor of age 18-55 Exclusion Criteria: * Type C/D Portal vein anatomy * Left sided Gallbladder * Right Posterior Graft * Recipients undergoing Hepaticojejunostomy

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic liver disease and cirrhosis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cirrhosis of liver Fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic liver disease and cirrhosis Donor hepatectomy Liver transplant; complications

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • ILBS

    RECRUITING

    New Delhi, 110070, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.